However, treatment with a monoclonal antibody to human interleukin-5 (mepolizumab) did not result in clinical success in patients with AD (73), whereas blocking of the Th2 cytokine signaling with a monoclonal antibody against the IL-4/IL-13 receptor alpha chain shows high efficacy in patients with severe AD (74). Here, IL4 is linked to Alzheimer disease.